Targeting Primitive Chronic Myeloid Leukemia Cells by Effective Inhibition of a New AHI-1–BCR-ABL–JAK2 Complex

BACKGROUND: Imatinib mesylate (IM) induces clinical remission of chronic myeloid leukemia (CML). The Abelson helper integration site 1 (AHI-1) oncoprotein interacts with BCR-ABL and Janus kinase 2 (JAK2) to mediate IM response of primitive CML cells, but the effect of the interaction complex on the...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Min, Gallipoli, Paolo, DeGeer, Donna, Sloma, Ivan, Forrest, Donna L., Chan, Matthew, Lai, Damian, Jorgensen, Heather, Ringrose, Ashley, Wang, Hui Mi, Lambie, Karen, Nakamoto, Helen, Saw, Kyi Min, Turhan, Ali, Arlinghaus, Ralph, Paul, James, Stobo, Jon, Barnett, Michael J., Eaves, Allen, Eaves, Connie J, Holyoake, Tessa L., Jiang, Xiaoyan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2013
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3601953/
https://www.ncbi.nlm.nih.gov/pubmed/23446755
http://dx.doi.org/10.1093/jnci/djt006

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3601953/
https://www.ncbi.nlm.nih.gov/pubmed/23446755
http://dx.doi.org/10.1093/jnci/djt006

Ejemplares similares